Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium
暂无分享,去创建一个
[1] S. Atkin,et al. The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas , 2004, Journal of Clinical Pathology.
[2] S. Dudek,et al. Mitogen-Activated Protein Kinases in Endothelial Pathophysiology , 2003, Journal of Investigative Medicine.
[3] L. Deiana,et al. PKC/Raf/MEK/ERK signaling pathway modulates native-LDL-induced E2F-1 gene expression and endothelial cell proliferation. , 2003, Cardiovascular research.
[4] Q. Xue,et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts , 2003, Journal of Cancer Research and Clinical Oncology.
[5] D. Noonan,et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. , 2003, Endocrinology.
[6] S. Atkin,et al. Fluvastatin Induces Apoptosis of Vascular Endothelial Cells: Blockade by Glucocorticoids , 2003, Cardiovascular surgery.
[7] D. Barber,et al. Somatostatin, Acting at Receptor Subtype 1, Inhibits Rho Activity, the Assembly of Actin Stress Fibers, and Cell Migration* , 2002, The Journal of Biological Chemistry.
[8] M. Koizumi,et al. Antiangiogenic Effect of Octreotide Inhibits the Growth of Human Rectal Neuroendocrine Carcinoma , 2002, Digestion.
[9] L. Turnbull,et al. Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours , 2002, British Journal of Cancer.
[10] S. Atkin,et al. Somatostatin receptor 2 expression in the human endometrium through the menstrual cycle , 2002, Clinical endocrinology.
[11] S. Lamberts,et al. New somatostatin analogs: will they fulfil old promises? , 2002, European journal of endocrinology.
[12] M. Hejna,et al. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] E. Woltering,et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors , 2001, British Journal of Cancer.
[14] J. Laissue,et al. Erratum to: Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.
[15] S. Fox,et al. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. , 2001, The Lancet. Oncology.
[16] P. Stork,et al. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2 , 2000, Journal of Physiology-Paris.
[17] A. Buchan,et al. Somatostatin receptor subtype expression and function in human vascular tissue. , 2000, American journal of physiology. Heart and circulatory physiology.
[18] A. Griffioen,et al. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.
[19] J. Rivier,et al. Somatostatin receptor gene expression in neuroblastoma , 2000, Regulatory Peptides.
[20] C. Rabourdin-Combe,et al. sst5 somatostatin receptor mRNA induction by mitogenic activation of human T-lymphocytes , 1999, Peptides.
[21] S. Lamberts,et al. Immunohistochemical localization of somatostatin receptor sst2A in human rheumatoid synovium. , 1999, The Journal of rheumatology.
[22] D. Hoyer,et al. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. , 1998, European journal of pharmacology.
[23] A. Schally,et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] F. Basolo,et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] J. Laissue,et al. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. , 1996, Metabolism: clinical and experimental.
[26] R. Danesi,et al. The effects of the somatostatin analog octreotide on angiogenesis in vitro. , 1996, Metabolism: clinical and experimental.
[27] M. Dichter,et al. Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20 , 1996, Neuroscience.
[28] G. Bell,et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Laissue,et al. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor‐host interaction? , 1994, International journal of cancer.
[30] E. Woltering,et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. , 1991, The Journal of surgical research.
[31] E. Jaffe,et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.
[32] E. Woltering,et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action , 2004, Investigational New Drugs.
[33] J. Laissue,et al. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.
[34] L. Hofland,et al. Somatostatin receptor subtype expression in human tumors. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] B. Wolffenbuttel,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society , 2000 .